REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet Age-Related Macular Degeneration (AMD)
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet Age-Related Macular Degeneration (AMD)
REGENXBIO Inc. (NASDAQ:RGNX) today announced the publication of results from the Phase I/IIa trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (wet AMD). Two-year data were published in The Lancet in a paper titled "Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study." These positive study results informed the ongoing pivotal trials of ABBV-RGX-314, a potential one-time gene therapy, for the treatment of wet AMD.
REGENXBIO Inc.（纳斯达克股票代码：RGNX）今天宣布公布了I/IIa期试验的结果，该试验评估了用于治疗湿性年龄相关性黄斑变性（湿性AMD）的单剂量视网膜下层 ABBV-RGX-314 的安全性和耐受性。两年的数据发布于 这个 柳叶刀 在一篇题为 “通过视网膜下输送 RGX-314 治疗新生血管年龄相关性黄斑变性的基因疗法：1/2a 期剂量递增研究” 的论文中。这些积极的研究结果为正在进行的用于治疗湿性 AMD 的 ABBV-RGX-314（一种潜在的一次性基因疗法）的关键试验提供了信息。